Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Characteristics of cystic fibrosis-related diabetes: Data from two different sources the European cystic fibrosis society patient registry and German/Austrian diabetes prospective follow-up registry.

Prinz N, Zolin A, Konrad K, Nährlich L, Laubner K, Olesen HV, Bauer M, Jung A, Frischer T, Holl RW; ECFS patient registry and the DPV registry.

Pediatr Diabetes. 2019 May;20(3):255-262. doi: 10.1111/pedi.12831. Epub 2019 Mar 7.

PMID:
30761696
2.

Comparison of Two Pediatric Early Warning Systems: A Randomized Trial.

Jensen CS, Olesen HV, Aagaard H, Svendsen MLO, Kirkegaard H.

J Pediatr Nurs. 2019 Jan - Feb;44:e58-e65. doi: 10.1016/j.pedn.2018.11.001. Epub 2018 Nov 22.

PMID:
30471827
3.

Clinical profile of children experiencing in-hospital clinical deterioration requiring transfer to a higher level of care.

Jensen CS, Kirkegaard H, Aagaard H, Olesen HV.

J Child Health Care. 2018 Aug 19:1367493518794400. doi: 10.1177/1367493518794400. [Epub ahead of print]

PMID:
30124066
4.

Pediatric Early Warning Score Systems, Nurses Perspective - A Focus Group Study.

Jensen CS, Nielsen PB, Olesen HV, Kirkegaard H, Aagaard H.

J Pediatr Nurs. 2018 Feb 14. pii: S0882-5963(17)30643-7. doi: 10.1016/j.pedn.2018.02.004. [Epub ahead of print]

PMID:
29454507
5.

Colistin resistance in Pseudomonas aeruginosa and Achromobacter spp. cultured from Danish cystic fibrosis patients is not related to plasmid-mediated expression of mcr-1.

Pedersen MG, Olesen HV, Jensen-Fangel S, Nørskov-Lauritsen N, Wang M.

J Cyst Fibros. 2018 Mar;17(2):e22-e23. doi: 10.1016/j.jcf.2017.12.001. Epub 2017 Dec 15. No abstract available.

PMID:
29254822
6.

Inter-rater reliability of two paediatric early warning score tools.

Jensen CS, Aagaard H, Olesen HV, Kirkegaard H.

Eur J Emerg Med. 2019 Feb;26(1):34-40. doi: 10.1097/MEJ.0000000000000493.

PMID:
28763311
7.

A multicentre, randomised intervention study of the Paediatric Early Warning Score: study protocol for a randomised controlled trial.

Jensen CS, Aagaard H, Olesen HV, Kirkegaard H.

Trials. 2017 Jun 8;18(1):267. doi: 10.1186/s13063-017-2011-7.

8.

Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis.

Qvist T, Taylor-Robinson D, Waldmann E, Olesen HV, Hansen CR, Mathiesen IH, Høiby N, Katzenstein TL, Smyth RL, Diggle PJ, Pressler T.

J Cyst Fibros. 2016 May;15(3):380-5. doi: 10.1016/j.jcf.2015.09.007. Epub 2015 Oct 9.

9.

Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis.

Elborn JS, Bell SC, Madge SL, Burgel PR, Castellani C, Conway S, De Rijcke K, Dembski B, Drevinek P, Heijerman HG, Innes JA, Lindblad A, Marshall B, Olesen HV, Reimann AL, Solé A, Viviani L, Wagner TO, Welte T, Blasi F.

Eur Respir J. 2016 Feb;47(2):420-8. doi: 10.1183/13993003.00592-2015. Epub 2015 Oct 9.

10.

Outpatient parenteral antimicrobial therapy (OPAT) in patients with cystic fibrosis.

Pedersen MG, Jensen-Fangel S, Olesen HV, Tambe SD, Petersen E.

BMC Infect Dis. 2015 Jul 27;15:290. doi: 10.1186/s12879-015-1019-4.

11.

Future trends in cystic fibrosis demography in 34 European countries.

Burgel PR, Bellis G, Olesen HV, Viviani L, Zolin A, Blasi F, Elborn JS; ERS/ECFS Task Force on Provision of Care for Adults with Cystic Fibrosis in Europe.

Eur Respir J. 2015 Jul;46(1):133-41. doi: 10.1183/09031936.00196314. Epub 2015 Mar 18.

12.

Low socioeconomic status and lung function.

Taylor-Robinson DC, Thielen K, Pressler T, Olesen HV, Diggle PJ.

Eur Respir J. 2015 Mar;45(3):857-8. doi: 10.1183/09031936.00232014. No abstract available.

13.

Low socioeconomic status is associated with worse lung function in the Danish cystic fibrosis population.

Taylor-Robinson DC, Thielen K, Pressler T, Olesen HV, Diderichsen F, Diggle PJ, Smyth R, Whitehead M.

Eur Respir J. 2014 Nov;44(5):1363-6. doi: 10.1183/09031936.00063714. Epub 2014 Sep 3. No abstract available.

14.

The European Cystic Fibrosis Society Patient Registry: valuable lessons learned on how to sustain a disease registry.

Viviani L, Zolin A, Mehta A, Olesen HV.

Orphanet J Rare Dis. 2014 Jun 7;9:81. doi: 10.1186/1750-1172-9-81.

15.

The relative frequency of CFTR mutation classes in European patients with cystic fibrosis.

De Boeck K, Zolin A, Cuppens H, Olesen HV, Viviani L.

J Cyst Fibros. 2014 Jul;13(4):403-9. doi: 10.1016/j.jcf.2013.12.003. Epub 2014 Jan 16.

16.

Intravenous antibiotics given for 2 weeks do not eradicate persistent Staphylococcus aureus clones in cystic fibrosis patients.

Andersen C, Kahl BC, Olesen HV, Jensen-Fangel S, Nørskov-Lauritsen N.

Clin Microbiol Infect. 2014 May;20(5):O285-91. doi: 10.1111/1469-0691.12406. Epub 2013 Nov 4.

17.

Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis.

Wang M, Ridderberg W, Hansen CR, Høiby N, Jensen-Fangel S, Olesen HV, Skov M, Lemming LE, Pressler T, Johansen HK, Nørskov-Lauritsen N.

J Cyst Fibros. 2013 Dec;12(6):638-43. doi: 10.1016/j.jcf.2013.04.013. Epub 2013 May 31.

18.

Low occurrence of 'non-haemolytic Haemophilus haemolyticus' misidentified as Haemophilus influenzae in cystic fibrosis respiratory specimens, and frequent recurrence of persistent H. influenzae clones despite antimicrobial treatment.

Fenger MG, Ridderberg W, Olesen HV, Nørskov-Lauritsen N.

Int J Med Microbiol. 2012 Dec;302(7-8):315-9. doi: 10.1016/j.ijmm.2012.10.001. Epub 2012 Nov 20.

PMID:
23177564
19.

Reference percentiles for FEV(1) and BMI in European children and adults with cystic fibrosis.

Boëlle PY, Viviani L, Busson PF, Olesen HV, Ravilly S, Stern M, Assael BM, Barreto C, Drevinek P, Thomas M, Krivec U, Mei-Zahav M, Vibert JF, Clement A, Mehta A, Corvol H; French CF Modifier Gene Study Investigators; European CF Registry Working Group.

Orphanet J Rare Dis. 2012 Sep 7;7:64. doi: 10.1186/1750-1172-7-64.

20.

Gastrointestinal transit times and motility in patients with cystic fibrosis.

Hedsund C, Gregersen T, Joensson IM, Olesen HV, Krogh K.

Scand J Gastroenterol. 2012 Sep;47(8-9):920-6. doi: 10.3109/00365521.2012.699548. Epub 2012 Jul 2.

PMID:
22746323
21.

Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study.

Taylor-Robinson D, Whitehead M, Diderichsen F, Olesen HV, Pressler T, Smyth RL, Diggle P.

Thorax. 2012 Oct;67(10):860-6. doi: 10.1136/thoraxjnl-2011-200953. Epub 2012 May 3.

22.

Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment.

Ridderberg W, Bendstrup KE, Olesen HV, Jensen-Fangel S, Nørskov-Lauritsen N.

J Cyst Fibros. 2011 Dec;10(6):466-9. doi: 10.1016/j.jcf.2011.07.004. Epub 2011 Aug 10.

23.

Exercise and quality of life in patients with cystic fibrosis: A 12-week intervention study.

Schmidt AM, Jacobsen U, Bregnballe V, Olesen HV, Ingemann-Hansen T, Thastum M, Oluf Schiøtz P.

Physiother Theory Pract. 2011 Nov;27(8):548-56. doi: 10.3109/09593985.2010.545102. Epub 2011 Jul 3.

24.

A novel mutation in the connexin 26 gene (GJB2) in a child with clinical and histological features of keratitis-ichthyosis-deafness (KID) syndrome.

Koppelhus U, Tranebjaerg L, Esberg G, Ramsing M, Lodahl M, Rendtorff ND, Olesen HV, Sommerlund M.

Clin Exp Dermatol. 2011 Mar;36(2):142-8. doi: 10.1111/j.1365-2230.2010.03936.x. Epub 2010 Sep 16.

PMID:
20846357
25.

Gender differences in the Scandinavian cystic fibrosis population.

Olesen HV, Pressler T, Hjelte L, Mared L, Lindblad A, Knudsen PK, Laerum BN, Johannesson M; Scandinavian Cystic Fibrosis Study Consortium.

Pediatr Pulmonol. 2010 Oct;45(10):959-65. doi: 10.1002/ppul.21265.

PMID:
20672360
26.

Unusual distribution of Burkholderia cepacia complex species in Danish cystic fibrosis clinics may stem from restricted transmission between patients.

Nørskov-Lauritsen N, Johansen HK, Fenger MG, Nielsen XC, Pressler T, Olesen HV, Høiby N.

J Clin Microbiol. 2010 Aug;48(8):2981-3. doi: 10.1128/JCM.00383-10. Epub 2010 Jun 2.

27.

Serum-surfactant SP-D correlates inversely to lung function in cystic fibrosis.

Olesen HV, Holmskov U, Schiøtz PO, Sørensen GL.

J Cyst Fibros. 2010 Jul;9(4):257-62. doi: 10.1016/j.jcf.2010.03.011. Epub 2010 May 8.

28.

Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis.

McCormick J, Mehta G, Olesen HV, Viviani L, Macek M Jr, Mehta A; European Registry Working Group.

Lancet. 2010 Mar 20;375(9719):1007-13. doi: 10.1016/S0140-6736(09)62161-9.

PMID:
20304245
29.

Co-morbidity of cystic fibrosis and celiac disease in Scandinavian cystic fibrosis patients.

Fluge G, Olesen HV, Gilljam M, Meyer P, Pressler T, Storrösten OT, Karpati F, Hjelte L.

J Cyst Fibros. 2009 May;8(3):198-202. doi: 10.1016/j.jcf.2009.02.002. Epub 2009 Mar 19.

30.

Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden.

Knudsen PK, Olesen HV, Høiby N, Johannesson M, Karpati F, Laerum BN, Meyer P, Pressler T, Lindblad A; Scandinavian CF Study Consortium (SCFSC).

J Cyst Fibros. 2009 Mar;8(2):135-42. doi: 10.1016/j.jcf.2008.11.001. Epub 2009 Jan 20.

31.

Diagnostic significance of measurements of specific IgG antibodies to Pseudomonas aeruginosa by three different serological methods.

Pressler T, Karpati F, Granström M, Knudsen PK, Lindblad A, Hjelte L, Olesen HV, Meyer P, Høiby N; Scandinavian CF Study Consortium.

J Cyst Fibros. 2009 Jan;8(1):37-42. doi: 10.1016/j.jcf.2008.08.002. Epub 2008 Oct 5.

32.

Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients.

Nilsson E, Larsson A, Olesen HV, Wejåker PE, Kollberg H.

Pediatr Pulmonol. 2008 Sep;43(9):892-9. doi: 10.1002/ppul.20875.

PMID:
18680179
33.

Viral and atypical bacterial infections in the outpatient pediatric cystic fibrosis clinic.

Olesen HV, Nielsen LP, Schiotz PO.

Pediatr Pulmonol. 2006 Dec;41(12):1197-204.

PMID:
17058280
34.

The mannan-binding lectin pathway and lung disease in cystic fibrosis--disfunction of mannan-binding lectin-associated serine protease 2 (MASP-2) may be a major modifier.

Olesen HV, Jensenius JC, Steffensen R, Thiel S, Schiøtz PO.

Clin Immunol. 2006 Dec;121(3):324-31. Epub 2006 Oct 12.

PMID:
17045845
35.

[Enterococcal infections. Clinical findings and treatment considering antibiotic resistance in Denmark].

Olesen HV, Møller JK.

Ugeskr Laeger. 2002 Apr 29;164(18):2386-90. Review. Danish.

PMID:
12024841
36.

Childhood hypersensitivity pneumonitis probably caused by cat hair.

Olesen HV, Thelle T, Møller JC.

Acta Paediatr. 1998 Jul;87(7):811-3.

PMID:
9722259

Supplemental Content

Loading ...
Support Center